Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691276 | 1.00 | TLR2 (0.46) | TLR2CASP3MDM2MDM4TP53 | |
| SCHEMBL30948677 | 1.00 | TLR2 (0.46) | TLR2CASP3MDM2MDM4TP53 | |
| SCHEMBL30919289 | 0.96 | PTPN1 (0.45) | TLR2CASP3 | |
| SCHEMBL3049634 | 0.94 | TLR2 (0.46) | TLR2CASP3MDM2HDAC1HDAC2 | |
| SCHEMBL18451149 | 0.93 | CASP3 (0.41) | TLR2CASP3 | |
| SCHEMBL19615686 | 0.92 | PTPN1 (0.49) | TLR2 | |
| SCHEMBL18452611 | 0.92 | PTPN1 (0.49) | TLR2 | |
| SCHEMBL18476829 | 0.92 | PTPN1 (0.49) | TLR2 | |
| SCHEMBL30948796 | 0.92 | CASP3 (0.46) | TLR2CASP3MDM2MDM4TP53 | |
| SCHEMBL26940363 | 0.92 | CASP3 (0.46) | TLR2CASP3MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
| EP-1648924-B1 | DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME | UNIV ASTON (GB) | 2008-07-30 | — | — | EP | disclosed |
| EP-1648924-A2 | DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME | The Nottingham Trent University (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004113363-A2 | DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME | THE NOTTINGHAM TRENT UNIVERSITY (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | TLR2 1929/4885CASP3 1245/4885MDM2 3407/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.